Hims & Hers (HIMS) is a compelling multi-year investment due to its strong revenue growth, substantial cash reserves, and a strategic partnership with Novo Nordisk that legitimizes its weight loss vertical and resolves legal risks.
Source Post
Is Hims & Hers Health Inc HIMS A Good Time To Buy Now? HIMS Stock Analysis
Mar 15, 2026
Hims & Hers Health Inc. (HIMS) experienced a significant 40% single-day stock surge following a new partnership with Novo Nordisk, which grants them access to sell branded GLP-1 weight loss drugs. Despite previous concerns about margin compression and a soft Q1 guidance, the company's strong revenue growth, substantial cash reserves, and a defensible competitive moat position it well for long-term growth, particularly within the booming weight loss sector. The analysis suggests HIMS is a compelling multi-year hold, leveraging the global adoption of GLP-1 drugs.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
HIMSbuy opened Mar 15, 2026
+18.37%